Repositioning of strongly integrated drugs against achromatopsia (CNGB3)

• Main Authors: Bibi Zainab, Zainab Ayaz, Anum Munir, Ahmed Hossam Mahmoud, Mohamed Soliman Elsheikh, Azhar Mehmood, Sajid Khan, Muhammad Rizwan, Kainat Jahangir, Arshad Mehmood Abbasi
• Format: Article
• Language: English
• Published: Elsevier 2020-04-01
• Series: Journal of King Saud University: Science
• Online Access: http://www.sciencedirect.com/science/article/pii/S1018364720300239

Achromatopsia (ACHM) is a genetically heterogeneous visual disorder, also known as rod monochromatism, in which human get affected due to cone cells. Mutation in five genes viz. CNGA3, CNGB3, GNAT2, PDE6C, and PDE6H have been reported in ACHM. These genes encode essential constitutes of the cone-specific photo transduction cascade. Present study was focused on CNGB3 gene that accounts 40%-50% mutations of all ACHM cases. A new approach for analyzing drug-drug interactions based on modularity was adopted. This approach depends on the behavioral relationship of drugs against CNGB3 for ACHM, particularly the ADME and toxicity between drugs. Data of 2475 compounds were retrieved, out of which 185 were selected on the basis of Lipinski rule of five. In total, eight clusters were made for which the strongly interacted DDI networks were build based on their modularity values. Strong DDI and minimum toxic values indicates that 5 drugs are effective, but on the basis of docking only 2 drugs indicated no bumps, which shows that they are most appropriate for treating ACHM. Our findings revealed that drug-drug interactions disclose the intervention of drug nature and can also successfully diagnose new indications and more convincing drugs for other diseases as well. Keywords: Achromatopsia, CNGB3, In silico, Integrated drugs